Precigen, a biotechnology company headquartered in Germantown, Maryland, focuses on synthetic biology technologies and develops therapies for urgent diseases. Founded in 2013, it operates through Biopharmaceuticals and Exemplar segments.
Randal J Kirk bought 16,691,667 shares of PGEN on 30 December at $0.00 per share, worth a total of $0. They now own 16,666,667 PGEN shares, or a 66767% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
